IRulya Therapeutics QNCX Income Statement (2018-2026)

NASDAQ QNCX
$34.45 +2.42 (+7.56%)
At close: Oct 19, 2026 · 4:00 PM EDT
Reported Financials

Quince Therapeutics Quarterly Income Statement

Periods 34 quarters
Latest Jun 2026

Quince Therapeutics reported net income of -$75.51M for the quarter ended Jun 2026. This income statement covers 34 quarters of results from Mar 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating items
Research & DevelopmentR&D
14.04M15.21M12.76M2.45M7.20M3.23M1.35M1.43M3.43M3.70M4.15M4.92M5.83M8.15M6.55M8.08M12.60M6.85M5.46M
Share-based Compensation (IS)Stock Comp.
1.22M1.12M1.13M1.39M1.27M1.26M1.19M1.29M12.09M
Selling, General & AdministrativeSG&A
7.64M8.33M9.11M4.34M9.01M3.83M4.23M4.66M4.91M4.97M4.70M3.63M4.28M4.79M3.34M3.28M3.64M4.27M16.63M
Restructuring CostsRestructuring
-1.31M
Other Operating ExpensesOther Opex
0.83M5.90M1.58M2.55M2.22M-2.68M1.90M1.92M0.53M2.10M3.12M-64.33M
Operating ExpensesOpex
21.68M23.54M21.86M7.62M16.21M12.96M5.58M6.09M9.92M11.22M28.19M5.86M12.01M14.86M10.43M13.43M19.35M14.59M79.78M
Operating IncomeOp. Inc
-21.68M-23.54M-21.86M-16.26M-7.62M-6.32M-12.96M-5.58M-6.09M-9.92M-11.22M-28.19M-5.86M-12.01M-14.86M-10.43M-13.43M-19.35M-14.59M-79.78M
EBIT
-21.68M-23.54M-21.86M-16.26M-7.62M-6.32M-12.96M-5.58M-6.09M-9.92M-11.22M-28.19M-5.86M-12.01M-14.86M-10.43M-13.43M-19.35M-14.59M-79.78M
Non-operating items
Non Operating Interest Expenses
Goodwill impairment chargesGoodwill Impair.
17.13M
Interest & Investment IncomeInt & Inv Inc
0.13M0.11M0.07M0.15M0.32M0.54M0.70M0.81M0.96M1.01M0.89M0.82M0.68M0.54M0.41M0.31M0.30M0.23M0.16M0.58M
Other Non Operating IncomeOther Non Op Inc.
-0.16M0.04M0.15M-0.74M-0.62M0.25M-0.25M-0.11M-0.22M0.40M-0.40M0.09M0.15M-0.52M-0.09M4.44M-0.06M22.16M-29.40M-3.05M
Net income details
EBT
-21.71M66.55M-21.64M-16.85M-7.92M-5.53M-12.50M-4.89M-5.35M-8.84M-11.12M-27.69M-5.48M-12.45M-14.98M-15.98M-13.49M-36.31M30.57M-75.41M
Tax ProvisionsTaxes
-0.28M-0.25M0.05M0.03M0.04M0.01M0.01M0.05M0.07M-0.05M3.15M-5.34M0.10M
Profit After TaxPAT
-21.71M66.55M-21.64M-16.56M-7.92M-5.53M-12.25M-4.89M-5.35M-8.89M-11.15M-27.73M-5.49M-12.46M-15.03M-16.05M-13.44M-39.46M35.91M-75.51M
Income from Continuing OperationsIncome (Continuing)
-21.71M66.55M-21.64M-16.56M-7.92M-5.53M-12.25M-4.89M-5.35M-8.89M-11.15M-27.73M-5.49M-12.46M-15.03M-16.05M-13.44M-39.46M35.91M-75.51M
Consolidated Net IncomeConsol Net Inc.
-21.71M66.55M-21.64M-16.56M-7.92M-5.53M-12.25M-4.89M-5.35M-8.89M-11.15M-27.73M-5.49M-12.46M-15.03M-16.05M-13.44M-39.46M35.91M-75.51M
Income towards Parent CompanyParent Net Inc
-21.71M-23.40M-21.64M-16.56M-7.92M-5.53M-12.25M-4.89M-5.35M-8.89M-11.15M-27.73M-5.49M-12.46M-15.03M-16.05M-13.44M-39.46M35.91M-75.49M
Net Income towards Common StockholdersNet Income
-21.71M-23.40M-21.64M-16.56M-7.92M-5.53M-12.25M-4.89M-5.35M-8.89M-11.15M-27.73M-5.49M-12.46M-15.03M-16.05M-13.44M-39.46M32.79M-75.49M
Additional items
EPS (Basic)
-145.84-157.47-143.63-102.04-44.48-33.04-68.35-27.21-29.67-47.77-51.84-128.68-25.45-57.59-68.41-68.75-49.83-157.5371.91-12.31
EPS (Diluted)
-145.84-157.47-143.63-102.04-44.48-33.04-68.35-27.21-29.67-47.77-51.84-128.68-25.45-57.59-68.41-68.75-49.83-157.5371.37-12.31
Shares Outstanding
0.15M0.15M0.15M0.16M0.18M0.17M0.18M0.18M0.18M0.19M0.22M0.22M0.22M0.22M0.22M0.23M0.27M0.25M0.46M6.13M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.15M0.15M0.15M0.16M0.18M0.17M0.18M0.18M0.18M0.19M0.22M0.22M0.22M0.22M0.22M0.23M0.27M0.25M0.46M6.13M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.15M0.15M0.15M0.18M0.18M0.18M0.18M0.18M0.18M0.21M0.22M0.22M0.22M0.22M0.22M0.27M0.27M0.28M0.46M6.13M
EBITDA
-21.59M-23.46M-21.83M-16.17M-7.58M-6.28M-12.94M-5.58M-6.09M-9.62M-11.18M-28.15M-5.78M-12.00M-14.83M-10.39M-13.39M-19.31M-14.55M-79.74M
Interest ExpensesInt Expense

Quince Therapeutics Income Statement API

Pull Quince Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=QNCX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY